Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Randomised Phase III Trial Of Concurrent Chemoradiotherapy With Extended Nodal Irradiation And Erlotinib In Patients With Inoperable Oesophageal Squamous Cell Cancer.

S. Wu, L. Wang, H. Luo, C. Xie, Xue-bang Zhang, W. Hu, An-ping Zheng, Duo-jie Li, Hong-yan Zhang, C. Xie, Xilong Lian, D. Du, M. Chen, X. Bian, B. Tan, H. Jiang, H. Zhang, J. Wang, Z. Jing, B. Xia, N. Zhang, P. Zhang, W. Li, Fu-jun Zhao, Z. Tian, H. Liu, Ke-Wei Huang, Jin Hu, Rui-fei Xie, Lin Du, G. Li
Published 2018 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
BACKGROUND This randomised phase III study was conducted to investigate the efficacy of extended nodal irradiation (ENI) and/or erlotinib in inoperable oesophageal squamous cell cancer (ESCC). PATIENTS AND METHODS Patients with histologically confirmed locally advanced ESCC or medically inoperable disease were randomly assigned (ratio 1:1:1:1) to one of four treatment groups: group A, radiotherapy adoption of ENI with two cycles of concurrent TP chemotherapy (paclitaxel 135 mg/m2 day 1 and cisplatin 20 mg/m2 days 1-3, every 4 weeks) plus erlotinib (150 mg per day during chemoradiotherapy); group B, radiotherapy adoption of ENI with two cycles of concurrent TP; group C, radiotherapy adoption of conventional field irradiation (CFI) with two cycles of concurrent TP plus erlotinib; group D, radiotherapy adoption of CFI with two cycles of concurrent TP. RESULTS A total of 352 patients (88 assigned to each treatment group) were enrolled. The 2-year overall survival rates of group A, B, C and D were 57.8%, 49.9%, 44.9% and 38.7%, respectively (P = 0.015). Group A significantly improved 2-year overall survival compared with group D. The ENI significantly improved overall survival in patients with inoperable ESCC (P = 0.014). The addition of erlotinib significantly decreased loco-regional recurrence (P = 0.042). Aside from rash and radiation oesophagitis, the incidence of grade 3 or greater toxicities did not differ among 4 groups. CONCLUSION Chemoradiotherapy with ENI and erlotinib might represent a substantial improvement on the standard of care for inoperable ESCC. ENI alone should be adopted in concurrent chemoradiotherapy for ESCC patients.
This paper references
10.1016/j.ijrobp.2011.04.032
Retrospective analysis of outcome differences in preoperative concurrent chemoradiation with or without elective nodal irradiation for esophageal squamous cell carcinoma.
Feng-Ming Hsu (2011)
10.1097/00000658-199409000-00012
Radical Lymph Node Dissection for Cancer of the Thoracic Esophagus
H. Akiyama (1994)
10.1001/JAMA.281.17.1623
Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group.
J. Cooper (1999)
10.1016/j.canlet.2014.11.045
Involved field irradiation for the treatment of esophageal cancer: is it better than elective nodal irradiation?
Liyang Jiang (2015)
10.1200/JCO.2014.56.7156
Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer.
K. Sudo (2014)
10.1201/B11800-18
Factorial Designs with Time-to-Event Endpoints
S. Green (2012)
10.1016/S1470-2045(13)70136-0
Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial.
T. Crosby (2013)
10.1093/jnci/92.3.205
New Guidelines to Evaluate the Response to Treatment in Solid Tumors.
P. Therasse (2000)
10.1111/dote.12471
Concurrent chemoradiotherapy with elective lymph node irradiation for esophageal cancer: a systemic review and pooled analysis of the literature.
Dexi Du (2017)
10.1016/j.radonc.2016.04.042
Does higher radiation dose lead to better outcome for non-operated localized esophageal squamous cell carcinoma patients who received concurrent chemoradiotherapy? A population based propensity-score matched analysis.
C. Chen (2016)
10.1002/cncr.25602
A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus
D. Ilson (2011)
10.1016/S1470-2045(14)70028-2
Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.
T. Conroy (2014)
10.1002/cncr.22445
Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas
K. Wang (2007)
10.1200/JCO.2014.32.3_SUPPL.LBA6
The initial report of RTOG 0436: A phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for patients with esophageal cancer treated without surgery.
M. Suntharalingam (2014)
10.1002/sim.5762
Model selection in competing risks regression.
D. Kuk (2013)
Expression and significance of epidermal growth factor receptor and its variant III in human esophageal carcinoma
Duan Xiao-yi (2009)
10.18632/ONCOTARGET.9798
A phase II study of concurrent chemoradiotherapy and erlotinib for inoperable esophageal squamous cell carcinoma.
Chuanhua Zhao (2015)
10.1158/0008-5472.CAN-04-3547
Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).
P. Chinnaiyan (2005)
10.1016/j.ijrobp.2009.10.012
Phase II study of concurrent chemoradiation in combination with erlotinib for locally advanced esophageal carcinoma.
G. Li (2010)
10.1002/ijc.21454
EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus
Mitsuhiko Hanawa (2006)
10.1159/000351617
Erlotinib and Radiation Therapy for Elderly Patients with Esophageal Cancer - Clinical and Correlative Results from a Prospective Multicenter Phase 2 Trial
R. Iyer (2013)
10.4149/neo_2012_065
Epidermal growth factor receptor (EGFR) expression and mutations in the EGFR signaling pathway in correlation with anti-EGFR therapy in head and neck squamous cell carcinomas.
P. Smilek (2012)
10.1002/cncr.28471
Phase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer
A. Nogueira-Rodrigues (2014)
10.1016/j.ijrobp.2015.02.005
Adding Erlotinib to Chemoradiation Improves Overall Survival but not Progression-Free Survival in Stage III Non-Small-Cell Lung Cancer
R. Komaki (2015)
10.1038/sj.bjc.6601461
Definitive chemoradiation in patients with inoperable oesophageal carcinoma
T. Crosby (2004)
10.1200/JCO.20.5.1167
INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy.
B. Minsky (2002)



This paper is referenced by
10.1007/s12029-020-00464-2
Patterns of Recurrence in Locally Advanced Resectable Oesophageal Carcinoma: Retrospective Review from a Tertiary Cancer Centre in South India
Anindita Das (2020)
10.3892/ol.2020.12277
TERT promoter regulating melittin expression induces apoptosis and G0/G1 cell cycle arrest in esophageal carcinoma cells
Chao Zhou (2021)
10.1038/s41416-020-01054-6
Chemoradiotherapy with extended nodal irradiation and/or erlotinib in locally advanced oesophageal squamous cell cancer: long-term update of a randomised phase 3 trial.
C. Xie (2020)
10.1007/s00280-020-04187-w
Interactions between anti-EGFR therapies and cytotoxic chemotherapy in oesophageal squamous cell carcinoma: why clinical trials might have failed and how they could succeed
Madusha Meemanage (2020)
10.1016/j.ejca.2018.03.028
More is more? Pushing chemoradiotherapy of oesophageal squamous cell carcinoma forward.
F. Lordick (2018)
10.3389/fphar.2019.00864
Wee1 Inhibitor AZD1775 Effectively Inhibits the Malignant Phenotypes of Esophageal Squamous Cell Carcinoma In Vitro and In Vivo
Shuning Bi (2019)
10.1016/j.ebiom.2019.05.023
Sub-region based radiomics analysis for survival prediction in oesophageal tumours treated by definitive concurrent chemoradiotherapy
C. Xie (2019)
Madusha Meemanage1 · Lindsay C. Spender1 · Diane Collinson2 · Joanna Iannetta1 · Pranavi Challapalli1 · Julie Turbitt2 · Caroline Clark2 · Mark Baxter1 · Graeme Murray3 · Shaun Walsh4 · Zofia Miedzybrodzka2 · Russell D. Petty1
Meemanage (2020)
Semantic Scholar Logo Some data provided by SemanticScholar